Jivraj K T, Noseworthy T W, Friesen E G, Shustack A S, Konopad E M, Johnston R G
Department of Adult Intensive Care, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Drug Intell Clin Pharm. 1987 Dec;21(12):974-5. doi: 10.1177/106002808702101208.
Agranulocytosis associated with spironolactone administration is described in a 57-year-old man. Four days after initiation of spironolactone, leukocyte counts decreased from 8.2 to 2.3 X 10(9)/L with 6% neutrophils. Spironolactone, domperidone, and prochlorperazine were discontinued. Domperidone and prochlorperazine were reintroduced and there was concomitant improvement of the leukocyte and neutrophil counts. Substitution of triamterene for spironolactone was not associated with recurrent leukopenia. The potential association of spironolactone with granulocytopenia warrants increased awareness of this rare but serious adverse drug reaction.
一名57岁男性出现了与服用螺内酯相关的粒细胞缺乏症。在开始服用螺内酯4天后,白细胞计数从8.2降至2.3×10⁹/L,中性粒细胞占6%。停用了螺内酯、多潘立酮和氯丙嗪。重新引入多潘立酮和氯丙嗪后,白细胞和中性粒细胞计数随之改善。用氨苯蝶啶替代螺内酯未出现复发性白细胞减少。螺内酯与粒细胞减少之间的潜在关联值得提高对这种罕见但严重的药物不良反应的认识。